Search: WFRF:(Therkildsen Christina)
> (2020-2023) >
Mismatch repair def...
-
Rasmussen, MariaCopenhagen University Hospital
(author)
Mismatch repair deficiency testing in Lynch syndrome-associated urothelial tumors
- Article/chapterEnglish2023
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:lup.lub.lu.se:b134597d-228d-4add-baf5-28a3da5d4169
-
https://lup.lub.lu.se/record/b134597d-228d-4add-baf5-28a3da5d4169URI
-
https://doi.org/10.3389/fonc.2023.1147591DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:art swepub-publicationtype
-
Subject category:ref swepub-contenttype
Notes
-
Introduction: Lynch syndrome-associated cancer develops due to germline pathogenic variants in one of the mismatch repair (MMR) genes, MLH1, MSH2, MSH6 or PMS2. Somatic second hits in tumors cause MMR deficiency, testing for which is used to screen for Lynch syndrome in colorectal cancer and to guide selection for immunotherapy. Both MMR protein immunohistochemistry and microsatellite instability (MSI) analysis can be used. However, concordance between methods can vary for different tumor types. Therefore, we aimed to compare methods of MMR deficiency testing in Lynch syndrome-associated urothelial cancers. Methods: Ninety-seven urothelial (61 upper tract and 28 bladder) tumors diagnosed from 1980 to 2017 in carriers of Lynch syndrome-associated pathogenic MMR variants and their first-degree relatives (FDR) were analyzed by MMR protein immunohistochemistry, the MSI Analysis System v1.2 (Promega), and an amplicon sequencing-based MSI assay. Two sets of MSI markers were used in sequencing-based MSI analysis: a panel of 24 and 54 markers developed for colorectal cancer and blood MSI analysis, respectively. Results: Among the 97 urothelial tumors, 86 (88.7%) showed immunohistochemical MMR loss and 68 were successfully analyzed by the Promega MSI assay, of which 48 (70.6%) were MSI-high and 20 (29.4%) were MSI-low/microsatellite stable. Seventy-two samples had sufficient DNA for the sequencing-based MSI assay, of which 55 (76.4%) and 61 (84.7%) scored as MSI-high using the 24-marker and 54-marker panels, respectively. The concordance between the MSI assays and immunohistochemistry was 70.6% (p = 0.003), 87.5% (p = 0.039), and 90.3% (p = 1.00) for the Promega assay, the 24-marker assay, and the 54-marker assay, respectively. Of the 11 tumors with retained MMR protein expression, four were MSI-low/MSI-high or MSI-high by the Promega assay or one of the sequencing-based assays. Conclusion: Our results show that Lynch syndrome-associated urothelial cancers frequently had loss of MMR protein expression. The Promega MSI assay was significantly less sensitive, but the 54-marker sequencing-based MSI analysis showed no significant difference compared to immunohistochemistry. Data from this study alongside previous studies, suggest that universal MMR deficiency testing of newly diagnosed urothelial cancers, using immunohistochemistry and/or sequencing-based MSI analysis of sensitive markers, offer a potentially useful approach to identification of Lynch syndrome cases.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Sowter, PeterUniversity of Newcastle upon Tyne
(author)
-
Gallon, RichardUniversity of Newcastle upon Tyne
(author)
-
Durhuus, Jon AmbækCopenhagen University Hospital,University of Copenhagen
(author)
-
Hayes, ChristineUniversity of Newcastle upon Tyne
(author)
-
Andersen, OveCopenhagen University Hospital
(author)
-
Nilbert, MefLund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments(Swepub:lu)onk-mni
(author)
-
Schejbel, LoneGentofte Hospital
(author)
-
Høgdall, EstridGentofte Hospital
(author)
-
Santibanez-Koref, MauroUniversity of Newcastle upon Tyne
(author)
-
Jackson, Michael S.University of Newcastle upon Tyne
(author)
-
Burn, JohnUniversity of Newcastle upon Tyne
(author)
-
Therkildsen, ChristinaCopenhagen University Hospital(Swepub:lu)med-cnt
(author)
-
Copenhagen University HospitalUniversity of Newcastle upon Tyne
(creator_code:org_t)
Related titles
-
In:Frontiers in Oncology132234-943X
Internet link
Find in a library
To the university's database
- By the author/editor
-
Rasmussen, Maria
-
Sowter, Peter
-
Gallon, Richard
-
Durhuus, Jon Amb ...
-
Hayes, Christine
-
Andersen, Ove
-
show more...
-
Nilbert, Mef
-
Schejbel, Lone
-
Høgdall, Estrid
-
Santibanez-Koref ...
-
Jackson, Michael ...
-
Burn, John
-
Therkildsen, Chr ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
Frontiers in Onc ...
- By the university
-
Lund University